The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Alifirova V.M.

Siberian State Medical University

Kamenskikh E.M.

Siberian State Medical University

Koroleva E.S.

Siberian State Medical University

Evaluation of serum neurofilament light chains levels for diagnosis, treatment monitoring and prognosis in multiple sclerosis

Authors:

Alifirova V.M., Kamenskikh E.M., Koroleva E.S.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(10‑2): 7‑13

DOI: 10.17116/jnevro20191191027

Read: 6149 times

Download PDF (RU)
Contact the author
Table of contents

EVALUATION OF SERUM NEUROFILAMENT LIGHT CHAINS LEVELS FOR DIAGNOSIS, TREATMENT MONITORING AND PROGNOSIS IN MULTIPLE SCLEROSIS
EVALUATION OF SERUM NEUROFILAMENT LIGHT CHAINS LEVELS FOR DIAGNOSIS, TREATMENT MONITORING AND PROGNOSIS IN MULTIPLE SCLEROSIS

To cite this article:

Alifirova VM, Kamenskikh EM, Koroleva ES. Evaluation of serum neurofilament light chains levels for diagnosis, treatment monitoring and prognosis in multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(10‑2):7‑13. (In Russ.)
https://doi.org/10.17116/jnevro20191191027

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
New aspe­cts of psoriasis pathogenesis: meta­bolomic profiling in dermatology. Russian Journal of Clinical Dermatology and Vene­reology. 2024;(5):526-531
Low-level laser therapy in multiple scle­rosis: justification and opti­mization methods of application. (Literature review). Problems of Balneology, Physiotherapy and Exercise Therapy. 2024;(5):45-56
Obje­ctive stru­ctural and functional moni­toring of poly­peptide reti­nal neuroprotective therapy in diabetic reti­nopathy. Russian Annals of Ophthalmology. 2024;(5):97-104
A pilot study of asso­ciations of markers of glial and neuronal dege­neration with executive functions in alco­hol use diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(10):74-79
Glial fibrillary acidic protein: is there a rela­tionship with the course of multiple scle­rosis and traumatic brain injury before the onset of multiple scle­rosis?. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(10):80-84
An indi­vidual approach to the diagnosis and treatment of an acute psychotic condition in a patient with a multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(10):97-102
Labo­ratory biomarkers for the prognosis of chro­nic heart failure. Labo­ratory Service. 2024;(3):5-16
The role of immuno-inflammatory factors in the deve­lopment of nega­tive symptoms in schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):42-48
Surgical treatment of seco­ndary trigeminal neuralgia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):203-209
Inflammatory aging. Part 1. The principal biochemical mechanisms. Russian Journal of Preventive Medi­cine. 2024;(12):145-150
Abstract:

Pathophysiological processes in multiple sclerosis frequently not diagnosed by clinicians become available for analysis only on the basis of paraclinical data (biomarkers). Nowadays neurofilament light chain can be defined as a promising biomarker for multiple sclerosis (MS). Neurofilaments are a structural part of normal neuronal processes consisting of light, intermediate and heavy chains. However, a damage of neurons such as neurodegeneration or axonal damage causes the escape of neurofilaments into extracellular space. Cutting-edge highly sensitive methods make it possible to detect neurofilament light chains not only in the cerebrospinal fluid but also in the blood serum thus opening the opportunities to utilize them in routine diagnosis in clinical practice. This review comprises existing data on the possible opportunities for research of serum neurofilament light chains in terms of exacerbations, effectiveness of basic therapy, assessment of individual disability, the atrophy of central nervous system structures. Also, there is some information on comparison of two methods: routine MRI of the brain with the contrast agents and detection of serum neurofilament light chains.

Keywords:

neurofilament light chains
multiple sclerosis
biological markers
neurodegeneration
axonal damage
demyelinization
brain cortex atrophy

Authors:

Alifirova V.M.

Siberian State Medical University

Kamenskikh E.M.

Siberian State Medical University

Koroleva E.S.

Siberian State Medical University

Close metadata

References:

  1. Doshi A, Chataway J. Multiple sclerosis, a treatable disease. Clinical Medicine. 2016;16(suppl 6):53-59. https://doi.org/10.7861/clinmedicine.16-6-s53
  2. Ciccarelli O. Multiple sclerosis in 2018: new therapies and biomarkers. The Lancet Neurology. 2019;18(1):10-12. https://doi.org/10.1016/s1474-4422(18)30455-1
  3. Khalil M, Salzer J. CSF neurofilament light. Neurology. 2016;87(11):1068-1069. https://doi.org/10.1212/wnl.0000000000003107
  4. Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T, Barro C, Kappos L, Comabella M, Fazekas F, Petzold A, Blennow K, Zetterberg H, Kuhle J. Neurofilaments as biomarkers in neurological disorders. Nature Reviews Neurology. 2018;14(10):577-589. https://doi.org/10.1038/s41582-018-0058-z
  5. Dong DL, Xu ZS, Chevrier MR, Cotter RJ, Cleveland DW, Hart GW. Glycosylation of mammalian neurofilaments. Localization of multiple O-linked N-acetylglucosamine moieties on neurofilament polypeptides L and M. J Biol Chem. 1993;268:16679-16687.
  6. Barry DM, Stevenson W, Bober BG, Wiese PJ, Dale JM, Barry GS, Byers NS, Strope JD, Chang R, Schulz DJ, Shah S, Calcutt NA, Gebremichael Y, Garcia ML. Expansion of Neurofilament Medium C Terminus Increases Axonal Diameter Independent of Increases in Conduction Velocity or Myelin Thickness. Journal of Neuroscience. 2012;32(18):6209-6219. https://doi.org/10.1523/jneurosci.0647-12.2012
  7. Rao MV, Campbell J, Yuan A, Kumar A, Gotow T, Uchiyama Y, Nixon RA. The neurofilament middle molecular mass subunit carboxyl-terminal tail domains is essential for the radial growth and cytoskeletal architecture of axons but not for regulating neurofilament transport rate. The Journal of Cell Biology. 2003;163(5):1021-1031. https://doi.org/10.1083/jcb.200308076
  8. Yuan A, Rao MV, Veeranna, Nixon RA. Neurofilaments and Neurofilament Proteins in Health and Disease. Cold Spring Harbor Perspectives in Biology. 2017;9(4):a018309. https://doi.org/10.1101/cshperspect.a018309
  9. Brown RH. Amyotrophic lateral sclerosis: Recent insights from genetics and transgenic mice. Cell. 1995;80(5):687-692. https://doi.org/10.1016/0092-8674(95)90346-1
  10. Beck R, Deek J, Safinya CR. Structures and interactions in «bottlebrush» neurofilaments: the role of charged disordered proteins in forming hydrogel networks. Biochemical Society Transactions. 2012;40(5):1027-1031. https://doi.org/10.1042/bst20120101
  11. Gnanapavan S, Grant D, Morant S, Furby J, Hayton T, Teunissen CE, Leoni V, Marta M, Brenner R, Palace J, Miller DH, Kapoor R, Giovannoni G. Biomarker Report from the Phase II Lamotrigine Trial in Secondary Progressive MS — Neurofilament as a Surrogate of Disease Progression. Derfuss T, ed. PLoS ONE. 2013;8(8):e70019. https://doi.org/10.1371/journal.pone.0070019
  12. Petzold A. Neurofilamentphosphoforms: Surrogate markers for axonal injury, degeneration and loss. Journal of the Neurological Sciences. 2005;233(1-2):183-198. https://doi.org/10.1016/j.jns.2005.03.015
  13. Teunissen CE, Khalil M. Neurofilaments as biomarkers in multiple sclerosis. Multiple Sclerosis Journal. 2012;18(5):552-556. https://doi.org/10.1177/1352458512443092
  14. Thouvenot E. Multiple sclerosis biomarkers: Helping the diagnosis? Revue Neurologique. 2018;174(6):364-371. https://doi.org/10.1016/j.neurol.2018.04.002
  15. Kuhle J, Plattner K, Bestwick JP, Lindberg RL, Ramagopalan SV, Norgren N, Nissim A, Malaspina A, Leppert D, Giovannoni G, Kappos L. A comparative study of CSF neurofilamentlight and heavy chain protein in MS. Multiple Sclerosis Journal. 2013;19(12):1597-1603. https://doi.org/10.1177/1352458513482374
  16. Compston A. Making progress on the natural history of multiple sclerosis. Brain. 2006;129(3):561-563. https://doi.org/10.1093/brain/awl034
  17. Giovannoni G. Peripheral blood neurofilament light chain levels: the neurologist’s C-reactive protein? Brain. 2018;141(8):2235-2237. https://doi.org/10.1093/brain/awy200
  18. Kuhlmann T. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain. 2002;125(10):2202-2212. https://doi.org/10.1093/brain/awf235
  19. Teunissen CE, Iacobaeus E, Khademi M, Brundin L, Norgren N, Koel-Simmelink MJA, Schepens M, Bouwman F, Twaalfhoven HAM, Blom HJ, Jakobs C, Dijkstr CD. Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis. Neurology. 2009;72(15):1322-1329. https://doi.org/10.1212/wnl.0b013e3181a0fe3f
  20. Gunnarsson M, Malmeström C, Axelsson M, Sundström P, Dahle C, Vrethem M, Olsson T, Piehl F, Norgren N, Rosengren L, Svenningsson A, Lycke J. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Annals of Neurology. 2010;69(1):83-89. https://doi.org/10.1002/ana.22247
  21. Håkansson I, Tisell A, Cassel P, Blennow K, Zetterberg H, Lundberg P, Dahle C, Vrethem M, Ernerudh J. Neurofilament light chain in cerebrospinal fluid and prediction of disease activity in clinically isolated syndrome and relapsing-remitting multiple sclerosis. European Journal of Neurology. 2017;24(5):703-712. https://doi.org/10.1111/ene.13274
  22. Novakova L, Axelsson M, Khademi M, Zetterberg H, Blennow K, Malmeström C, Piehl F, Olsson T, Lycke J. Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis. Journal of Neurochemistry. 2016;141(2):296-304. https://doi.org/10.1111/jnc.13881
  23. Cai L, Huang J. Neurofilament light chain as a biological marker for multiple sclerosis: a meta-analysis study. Neuropsychiatric Disease and Treatment. 2018;14:2241-2254. https://doi.org/10.2147/ndt.s173280
  24. Malmestrom C, Haghighi S, Rosengren L, Andersen O, Lycke J. Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS. Neurology. 2003;61(12):1720-1715. https://doi.org/10.1212/01.wnl.0000098880.19793.b6
  25. Novakova L, Zetterberg H, Sundström P, Axelsson M, Khademi M, Gunnarsson M, Malmestrom C, Svenningsson A, Olsson T, Piehl F, Blennow K, Lycke J. Monitoring disease activity in multiple sclerosis using serum neurofilament light protein. Neurology. 2017;89(22):2230-2237. https://doi.org/10.1212/wnl.0000000000004683
  26. Kuhle J, Disanto G, Lorscheider J, Stites T, Chen Y, Dahlke F, Francis G, Shrinivasan A, Radue EW, Giovannoni G, Kappos L. Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis. Neurology. 2015;84(16):1639-1643. https://doi.org/10.1212/wnl.0000000000001491
  27. Axelsson M, Malmeström C, Gunnarsson M, Zetterberg H, Sundström P, Lycke J, Svenningsson A. Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis. Multiple Sclerosis Journal. 2013;20(1):43-50. https://doi.org/10.1177/1352458513490544
  28. Olsson B, Malmeström C, Basun H, Annas P, Höglund K, Lannfelt L, Andreasen N, Zetterberg H, Blennow K. Extreme Stability of Chitotriosidase in Cerebrospinal Fluid makes it a Suitable Marker for Microglial Activation in Clinical Trials. Journal of Alzheimer’s Disease. 2012;32(2):273-276. https://doi.org/10.3233/jad-2012-120931
  29. Conductier G, Blondeau N, Guyon A, Nahon J-L, Rovère C. The role of monocyte chemoattractant protein MCP1/CCL2 in neuroinflammatory diseases. Journal of Neuroimmunology. 2010;224(1-2):93-100. https://doi.org/10.1016/j.jneuroim.2010.05.010
  30. Comabella M, Fernández M, Martin R, Rivera-Vallvé S, Borrás E, Chiva C, Julia E, Rovira A, Canto E, Carlos J, Alvarez-Cermeno JC, Villar LM, Tintore M, Montalban X. Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. Brain. 2010;133(4):1082-1093. https://doi.org/10.1093/brain/awq035
  31. Barro C, Benkert P, Disanto G, Tsagkas C, Amann M, Naegelin Y, Leppert D, Gobbi C, Granziera C, Yaldizli O, Michalak Z, Wuerfel J, Kappos L, Parmar K, Kuhle J. Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis. Brain. 2018;141(8):2382-2391. https://doi.org/10.1093/brain/awy154
  32. Disanto G, Barro C, Benkert P, Naegelin Y, Schädelin S, Giardiello A, Zecca C, Blennow K, Zetterberg H, Leppert D, Kappos L, Gobbi C, Kuhle J. Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis. Annals of Neurology. 2017;81(6):857-870. https://doi.org/10.1002/ana.24954
  33. Novakova L, Axelsson M, Khademi M, Zetterberg H, Blennow K, Malmeström C, Piehl F, Olsson T, Lycke J. Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis. Multiple Sclerosis Journal. 2016;23(1):62-71. https://doi.org/10.1177/1352458516639384
  34. De Flon P, Gunnarsson M, Laurell K, Söderström L, Birgander R, Lindqvist T, Krauss W, Dring A, Bergman J, Sundstrom P, Svenningsson A. Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab. Neurology. 2016;87(2):141-147. https://doi.org/10.1212/wnl.0000000000002832
  35. Romme Christensen J, Ratzer R, Bornsen L, Lyksborg M, Garde E, Dyrby TB, Hartwig RS, Pes S, Finn Sellebjerg. Natalizumab in progressive MS: Results of an open-label, phase 2A, proof-of-concept trial. Neurology. 2014;82(17):1499-1507. https://doi.org/10.1212/wnl.0000000000000361
  36. Mariotto S, Farinazzo A, Monaco S, Gajofatto A, Zanusso G, Schanda K, Capra R, Mancinelli C, Bonora A, Bombardi R, Reindl M, Ferrari S. Serum Neurofilament Light Chain in NMOSD and Related Disorders: Comparison According to Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Antibodies Status. Multiple Sclerosis Journal — Experimental, Translational and Clinical. 2017;3(4):205521731774309. https://doi.org/10.1177/2055217317743098
  37. Disanto G, Adiutori R, Dobson R, MartinelliV, Dalla Costa G, Runia T, Evdoshenko E, Thouvenot E, Trojano M, Norgren N, Teunissen C, Kappos L, Giovannoni G, Kuhle J. Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome. Journal of Neurology, Neurosurgery & Psychiatry. 2016;87(2):126-129. https://doi.org/10.1136/jnnp-2014-309690
  38. Petzold A. Neurofilamentphosphoforms: Surrogate markers for axonal injury, degeneration and loss. Journal of the Neurological Sciences. 2005;233(1-2):183-198. https://doi.org/10.1016/j.jns.2005.03.015
  39. Petzold A, Keir G, Green AJ., Giovannoni G, Thompson E. A specific EL SA for measuring neurofilament heavy chain phosphoforms. Journal of Immunological Methods. 2003;278(1-2):179-190. https://doi.org/10.1016/s0022-1759(03)00189-3
  40. Rosengren LE, Karlsson J-E, Karlsson J-O, Persson LI, Wikkelsø C. Patients with Amyotrophic Lateral Sclerosis and Other Neurodegenerative Diseases Have Increased Levels of Neurofilament Protein in CSF. Journal of Neurochemistry. 2002;67(5):2013-2018. https://doi.org/10.1046/j.1471-4159.1996.67052013.x
  41. Norgren N, Karlsson J-E, Rosengren L, Stigbrand T. Monoclonal Antibodies Selective for Low Molecular Weight Neurofilaments. Hybridoma and Hybridomics. 2002;21(1):53-59. https://doi.org/10.1089/15368590252917647
  42. Norgren N, Rosengren L, Stigbrand T. Elevated neurofilament levels in neurological diseases. Brain Research. 2003;987(1):25-31. https://doi.org/10.1016/s0006-8993(03)03219-0
  43. Petzold A, Tisdall MM, Girbes AR, Martinian L, Thom M, Kitchen N, Smith M. In vivo monitoring of neuronal loss in traumatic brain injury: a microdialysis study. Brain. 2011;134(2):464-483. https://doi.org/10.1093/brain/awq360
  44. Zucchi E, Lu C, Cho Y, Chang R, Adiutori R, Zubiri I, Ceroni M, Cereda C, Pansarasa O, Greensmith L, Malaspina A, Petzold A. A motor neuron strategy to save time and energy in neurodegeneration: adaptive protein stoichiometry. Journal of Neurochemistry. 2018;146(5):631-641. https://doi.org/10.1111/jnc.14542
  45. Petzold A, Keir G, Warren J, Fox N, Rossor MN. A Systematic Review and Meta-Analysis of CSF Neurofilament Protein Levels as Biomarkers in Dementia. Neurodegenerative Diseases. 2007;4(2-3):185-194. https://doi.org/10.1159/000101843
  46. Petzold A, Altintas A, Andreoni L, Bartos A, Berthele A, Blankenstein MA. Neurofilament ELISA validation. Journal of Immunological Methods. 2010;352(1-2):23-31. https://doi.org/10.1016/j.jim.2009.09.014
  47. Gaiottino J, Norgren N, Dobson R, Topping J, Nissim A, Malaspina A, Bestwick J, Monsch A, Regeniter A, Lindberg R, Kappos L, Leppert D, Petzold A, Giovannoni G, Kuhle J. Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases. Reindl M, ed. PLoS ONE. 2013;8(9):e75091. https://doi.org/10.1371/journal.pone.0075091
  48. Kuhle J, Gaiottino J, Leppert D, Petzold A, Bestwick JP, Malaspina A, Lu CH, Dobson R, Disanto G, Norgen N, Nissim A, Kappos L, Hurlbert J, Yong V, Giovannoni G, Casha S. Serum neurofilament light chain is a biomarker of human spinal cord injury severity and outcome. Journal of Neurology, Neurosurgery & Psychiatry. 2014;86(3):273-279. https://doi.org/10.1136/jnnp-2013-307454
  49. Kuhle J, Regeniter A, Leppert D, Mehling M, Kappos L, Lindberg RLP, Petzold A. A highly sensitive electrochemiluminescence immunoassay for the neurofilament heavy chain protein. Journal of Neuroimmunology. 2010;220 (1-2):114-119. https://doi.org/10.1016/j.jneuroim.2010.01.004
  50. Kuhle J, Leppert D, Petzold A, Regeniter A, Schindler C, Mehling M, Anthony D, Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis. Neurology. 2011;76(14):1206-1213. https://doi.org/10.1212/wnl.0b013e31821432ff
  51. Kuhle J, Nourbakhsh B, Grant D, Morant S, Barro C, Yaldizli Ö, Pelletier D, Giovannoni G, Waubant E, Gnanapavan S. Serum neurofilament is associated with progression of brain atrophy and disability in early MS. Neurology. 2017;88(9):826-831. https://doi.org/10.1212/wnl.0000000000003653
  52. Gisslén M, Price RW, Andreasson U, Norgren N, Nilsson S, Hagberg L, Fuchs D, Spudich S, Blennow K, Zetterberg H. Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study. EBioMedicine. 2016;3:135-140. https://doi.org/10.1016/j.ebiom.2015.11.036
  53. Kuhle J, Barro C, Andreasson U, Derfuss T, Lindberg R, Sandelius Å, Liman V, Norgen N, Blennow K, Zetterberg H. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clinical Chemistry and Laboratory Medicine (CCLM). 2016;54(10):1655-1661. https://doi.org/10.1515/cclm-2015-1195
  54. Rissin DM, Kan CW, Campbell TG, Howes SC, Fournier DR, Song L, Piech T, Patel P, Chang L, Rivnak A, Ferreli E, Randall J, Provucher D, walt D, Duffy D. Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nature Biotechnology. 2010;28(6):595-599. https://doi.org/10.1038/nbt.1641
  55. Lycke JN, Karlsson J-E, Andersen O, Rosengren LE. Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis. Journal of Neurology, Neurosurgery & Psychiatry. 1998;64(3):402-404. https://doi.org/10.1136/jnnp.64.3.402
  56. Kuhle J, Barro C, Disanto G, Mathias A, Soneson C, Bonnier G, Yaldizli O, Regeniter A, Derfuss T, Canales M, Schluep M, Du Pasquier R, Krueger G, Granziera Cl. Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity. Multiple Sclerosis Journal. 2016;22(12):1550-1559. https://doi.org/10.1177/1352458515623365
  57. Gisslén M, Price RW, Andreasson U, Norgren N, Nilsson S, Hagberg L, Fuchs D, Spudich S, Blennow K, Zetterberg H. Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study. EBioMedicine. 2016;3:135-140. https://doi.org/10.1016/j.ebiom.2015.11.036
  58. Lucchinetti CF, Popescu BFG, Bunyan RF, Moll NM, Roemer SF, Lassmann H, Bruck W, Parisi J, Scheithauer B, Giannini, Weigand S, Mandrekar S, Ransohoff R. Inflammatory Cortical Demyelination in Early Multiple Sclerosis. New England Journal of Medicine. 2011;365(23):2188-2197. https://doi.org/10.1056/nejmoa1100648
  59. Rocca MA, Battaglini M, Benedict RHB, De Stefano N, Geurts JJG, Henry RG, Horsfield M, Jenkinson M, Pagani E, Filippi M. Brain MRI atrophy quantification in MS. Neurology. 2016;88(4):403-413. https://doi.org/10.1212/wnl.0000000000003542
  60. Eshaghi A, Marinescu RV, Young AL, Firth NC, Prados F, Jorge Cardoso M. Progression of regional grey matter atrophy in multiple sclerosis. Brain. 2018;141(6):1665-1677. https://doi.org/10.1093/brain/awy088
  61. Varhaug KN, Barro C, Bjørnevik K, Myhr K-M, Torkildsen Ø, Wergeland S, Bindoff L, Kuhle J, Vedeler C. Neurofilament light chain predicts disease activity in relapsing-remitting MS. Neurology — Neuroimmunology Neuroinflammation. 2017;5(1):e422. https://doi.org/10.1212/nxi.0000000000000422
  62. Yabe JT, Chylinski T, Wang F-S, Pimenta A, Kattar SD, Linsley M-D, Chan W, Shea T. Neurofilaments Consist of Distinct Populations That Can Be Distinguished by C-Terminal Phosphorylation, Bundling, and Axonal Transport Rate in Growing Axonal Neurites. Journal of Neuroscience. 2001;21(7):2195-2205. https://doi.org/10.1523/jneurosci.21-07-02195.2001
  63. Tiedt S, Duering M, Barro C, Kaya AG, Boeck J, Bode FJ, Klein M, Dorn F, Gesierich B, Kellert L, Ertl-Wagner B, Goertier M, Petzold G, Kuhle J, Wollenweber F, Peters N, Dichgans M. Serum neurofilament light. Neurology. 2018;91(14):1338-1347. https://doi.org/10.1212/wnl.0000000000006282
  64. Feneberg E, Oeckl P, Steinacker P, Verde F, Barro C, Van Damme P. Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis. Neurology. 2017;90(1):22-30. https://doi.org/10.1212/wnl.0000000000004761
  65. Meeter LH, Dopper EG, Jiskoot LC, Sanchez-Valle R, Graff C, Benussi L. Neurofilament light chain: a biomarker for genetic frontotemporal dementia. Annals of Clinical and Translational Neurology. 2016;3(8):623-636. https://doi.org/10.1002/acn3.325
  66. Trentini A, Comabella M, Tintoré M, Koel-Simmelink MJA, Killestein J, Roos B, Rovira A, Korth C, Ottis P, Blankenstein M, Montalban X, Belini T Teunissen C. N-Acetylaspartate and neurofilaments as biomarkers of axonal damage in patients with progressive forms of multiple sclerosis. Journal of Neurology. 2014;261(12):2338-2343. https://doi.org/10.1007/s00415-014-7507-4
  67. Villar LM, Picón C, Costa-Frossard L, Alenda R, García-Caldentey J, Espiño M, Muriel A. Alvarez-Cermeno JC. Cerebrospinal fluid immunological biomarkers associated with axonal damage in multiple sclerosis. European Journal of Neurology. 2014;22(8):1169-1175. https://doi.org/10.1111/ene.12579
  68. Lu C-H, Macdonald-Wallis C, Gray E, Pearce N, Petzold A, Norgren N, Giovannoni G, Fratta P, Sidle K, Fish M, Orrel R, Howard R, Talbot K, Greensmith L, Kuhle J, Turner M, Malaspina A. Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis. Neurology. 2015;84(22):2247-2257. https://doi.org/10.1212/wnl.0000000000001642
  69. Basal E, Zalewski N, Kryzer TJ, Hinson SR, Guo Y, Dubey D, Bennaroch E, Lucchietti C, Pittock S, Lennon V, McKeon A. Paraneoplastic neuronal intermediate filament autoimmunity. Neurology. 2018;91(18):1677-1689. https://doi.org/10.1212/wnl.0000000000006435
  70. Mariotto S, Farinazzo A, Magliozzi R, Alberti D, Monaco S, Ferrari S. Serum and cerebrospinal neurofilament light chain levels in patients with acquired peripheral neuropathies. Journal of the Peripheral Nervous System. 2018;23(3):174-177. https://doi.org/10.1111/jns.12279
  71. Varhaug KN, Torkildsen Ø, Myhr K-M, Vedeler CA. Neurofilament Light Chain as a Biomarker in Multiple Sclerosis. Frontiers in Neurology. 2019;5(10):338. https://doi.org/10.3389/fneur.2019.00338
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.